FDA Approves Rituximab Plus Chemotherapy for Several Pediatric Hematologic Malignancies
On December 2, the U.S. Food and Drug Administration (FDA) approved rituximab (Rituxan) in combination with chemotherapy for pediatric patients (≥ 6 months to < 18 years old) with previously untreated, advanced-stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia.
DREAMseq Trial: In Advanced Melanoma With BRAF Mutations, Start With Immunotherapy
In the treatment of patients with advanced melanoma containing BRAF mutations, initial treatment with an immunotherapy combination...
Long-Term Follow-up of monarchE: Benefit of Abemaciclib Plus Endocrine Therapy Maintained in Early High-Risk Breast Cancer
Longer-term follow-up of the global phase III monarchE trial showed an increasing benefit for adding abemaciclib to endocrine therapy...
Effect of the COVID-19 Pandemic on Cancer Imaging
Significant decreases in CT imaging for cancer persisted even after the peak of the COVID-19 pandemic in 2020...
ASCO Coronavirus Resources
As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...
Suresh Ramalingam on Durable Responses in Metastatic NSCLC: Are We Getting Closer to a Cure?
Ajay Nooka on Maintenance Daratumumab After Initial Therapy for Transplant-Eligible Multiple Myeloma
Dario Trapani and Harold Burstein on Duration of Endocrine Therapy in Breast Cancer
Rana McKay on Adjuvant Immunotherapy: The Next Chapter in Advancements in RCC
Hannah Dzimitrowicz and Andrew Armstrong: Taking Akt-ion Against Prostate Cancer?
Sponsored Content
Sponsored by Iovance Biotherapeutics
Emerging Cell-Based Therapies for Non–Small Cell Lung Cancer
Sponsored by Helsinn
Practical Issues in the Use of FGFR Inhibitors for Advanced Cholangiocarcinoma
Results of a Restrictive Opioid Prescription Protocol for Patients With Cancer Undergoing Surgery
Seeing an opportunity to safely reduce the number of opioid doses prescribed to patients with cancer, researchers proposed a new pain management guideline for all patients undergoing surgery at Roswell Park Comprehensive Cancer Center. The results from the first 6 months of that effort, reported by ...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
Addition of Gemtuzumab Ozogamicin to Conventional Background Chemotherapy in Pediatric Patients With KMT2A-Rearranged AML
As reported in the Journal of Clinical Oncology by Pollard et al, a subgroup of pediatric patients with KMT2A-rearranged acute myeloid leukemia (AML) in the phase III Children’s Oncology Group AAML0531 trial had improved outcomes with the addition of the CD33-targeting agent gemtuzumab ozogamicin...
PET Response–Adapted Chemoradiotherapy for Esophageal and Esophagogastric Junction Adenocarcinoma
As reported in the Journal of Clinical Oncology by Karyn A. Goodman, MD, and colleagues, mature results of the phase II CALGB 80803/Alliance trial indicated that treatment guided by early positron-emission tomography (PET) assessment of response to induction neoadjuvant chemotherapy improved...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
Neoadjuvant Chemotherapy De-escalation Using F-18 FDG-PET Response–Based Strategy in HER2-Positive Breast Cancer
In the European phase II PHERGain study reported in The Lancet Oncology, Pérez-García et al found that an F-18 fluorodeoxyglucose positron-emission tomography (F-18 FDG-PET) response–based strategy may be able to identify patients with HER2-positive early breast cancer who may benefit from...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
